This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The short answer to #1 is that healthcare private equity firms operate in specific verticals with stable-ish cash flows, such as healthcare services, nursing facilities, medical devices, equipment, and healthcare IT. Areas like healthcare services and medical devices are fairly generalist and follow standard accounting and valuation.
Strained access to public markets and funding The IPO market remained relatively inactive in 2023, leading many life sciences companies looking to raise funds to turn to other exit strategies. Additional major acquisitions of 2023 included Pfizer’s acquisition of Seagen for $43 billion and Merck’s acquisition of Prometheus for $10.8
Private equity’s increased interest in life sciences , with PE buyers accounting for 47% of deal volume in the first half of 2021 , compared to a long?term 2021’s SPAC activity was most intense in the first quarter, with 298 SPAC IPOs priced and 97 deSPAC transactions announced in the first quarter alone. time highs in 2021.
2] Despite the downtrend, global tech M&A activity in 2022 remained strong relative to pre-pandemic levels and accounted for a record 20% of all global M&A activity. In 2022, however, IPOs or cash sales were not viable exit opportunities for many investors – particularly investors of underperforming or cash-burning investments.
Starting March 1st, 2025, insurers will be required to block the premium amount in the policyholder’s account and only debit it once underwriting is successfully completed. Effective from March 1, 2025, Bima-ASBA leverages UPI One-Time Mandates to block the required amount in the policyholders account at the time of application.
their Enterprise Values are not worth much for a long time): Hedge funds focusing on public biotech companies step into this process after the IPO part, which means they can bet on extreme value inflections based on binary outcomes. If you have an advanced medical or academic background (e.g., or Ph.D.),
We organize all of the trending information in your field so you don't have to. Join 38,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content